The Simply Good Foods Company (SMPL) — Investment Analysis
Analyst: Value-investing workflow (Buffett / Munger / Klarman lens) Date: 2026-06-06 · Exchange: NASDAQ · Currency: USD · Fiscal year ends late August Why flagged: deep-value screen (P/B 0.7, ~14% FCF yield) + Howard Marks / Oaktree NEW 0.38% position Q1 2026
1. Executive summary
Three-sentence thesis. Simply Good Foods is an asset-light, $1.45B-revenue branded nutrition company (Quest, Atkins, OWYN) that the market has repriced from a $34 growth darling to an $11.94 "broken-CPG" name after a 64% one-year drawdown and a $249M non-cash brand impairment ($187M OWYN + $62M Atkins) booked in Q2 FY2026. Strip the accounting noise and the underlying machine still throws off roughly $150M of free cash flow on under $21M of annual capex — a ~14% FCF yield — while management is aggressively retiring stock (11% of shares bought back since the fiscal year began) at prices it openly calls undervalued. The debate is binary: either Quest + OWYN (71% of sales, both growing double digits in consumption) carry the company past a shrinking Atkins and the brands hold value, or GLP-1 drugs and lost distribution turn the whole low-carb/high-protein franchise into a melting ice cube — and at today's price the market is paying you to find out.
Metrics dashboard (sources: AlphaVantage statements, Q2 FY2026 10-Q, price file):
| Metric | Value | Note |
|---|---|---|
| Price (2026-06-05) | $11.94 | -65% vs 52-wk high $34.12 |
| Shares out | 90.49M | down from 101.5M (Aug-25) on buybacks |
| Market cap | ~$1.08B | |
| Net debt (Feb-26) | ~$289M | $397M debt - $107M cash |
| Enterprise value | ~$1.37B | |
| Revenue (FY25 / TTM) | $1.45B / $1.42B | |
| Adj. EBITDA (TTM est.) | ~$220-235M | EV/EBITDA ~5.8-6.2x |
| FCF (FY25 / normalized) | $158M / ~$150M | FCF yield ~14% |
| Op margin (FY25) | 15.1% | gross margin ~35% |
| Reported EPS TTM | -$1.13 | distorted by $249M impairment |
| Adj. diluted EPS (Q1 FY26) | $0.39 | vs $0.49 PY |
| Net debt / EBITDA | ~1.2x | target "around a turn" |
| Tangible book | Negative | $1.85B goodwill+intangibles |
| Price / book | 0.7x | below stated book |
Verdict: WAIT (lean constructive). Quality grade B-. This is a genuinely cheap, cash-generative business with a real growth brand (Quest) trading near its bear-case DCF value, and Howard Marks's small toe-in is a reasonable distressed-value signal. But it is not a fortress: an accelerating Atkins decline, a freshly impaired OWYN acquisition that signals capital-allocation error, GLP-1 as an unquantifiable secular overhang, and debt-funded buybacks into falling EBITDA are real ways to lose money. I want either (a) a lower price that prices in a worse Atkins, or (b) one or two quarters of evidence that H2 FY2026 margin recovery and Quest/OWYN momentum are real before committing capital. Strong Buy < $9.50; Accumulate < $11.00.
2. Business model (primary source: FY2025 10-K, Q1/Q2 FY2026 filings)
Simply Good Foods is a "house of brands" in the nutritional-snacking and active-nutrition category. It does not manufacture most of its own product — it is an asset-light marketer/brand owner that outsources manufacturing to co-packers, which is why capex runs under 1.5% of sales ($20.5M FY25 on $1.45B revenue) and operating cash conversion is high.
Three brands:
- Quest — high-protein, low-sugar bars, chips/salty snacks, shakes, and confection. This is the growth engine: Q1 FY2026 net sales +10% on +12% consumption, leading in salty snacks. Highest protein content (45g shakes). Higher gross margin than Atkins.
- Atkins — the legacy low-carb/weight-management brand (bars, shakes, confections). Structurally declining: Q1 FY2026 consumption -19%, of which ~2/3 is lost distribution (notably the club channel, "almost fully passed by April"). Management is deliberately ceding shelf space — repurposing "Atkins tail" SKUs to faster-turning Quest/OWYN. 75% of Atkins sales still come from top-half-velocity SKUs.
- OWYN ("Only What You Need") — clean-label, plant-based RTD shakes, acquired in 2024 for ~$280M. Growing double-digit in consumption but hit by "velocity-related declines" and product-quality issues in early FY2026, and written down $187M in Q2 FY2026 — a candid admission the deal was overpaid.
Quest + OWYN now generate 71% of net sales and are the future; Atkins is the cash-and-runoff piece management is managing for profitability rather than growth.
3. Phase 1 — Risk analysis (inversion: how do we lose money here?)
I invert per Munger: assume the investment fails, and enumerate the routes.
Risk register (P x Impact)
| # | Risk | Mechanism | P(event, ~3yr) | Impact if it happens | Expected drag |
|---|---|---|---|---|---|
| R1 | GLP-1 demand destruction | Ozempic/Wegovy shrink appetite and the entire weight-management/low-carb category; Atkins thesis ("reach and maintain weight") gets disintermediated | 35% | -35% | -12.3% |
| R2 | Atkins decline accelerates | Distribution losses overshoot the planned ~20%; club/retail keeps cutting; brand becomes unsalvageable | 40% | -20% | -8.0% |
| R3 | OWYN was a value-destroying deal | $187M impairment already booked; further write-downs / integration drag; growth stalls | 30% | -12% | -3.6% |
| R4 | Margin compression persists | Cocoa + whey inflation + tariffs (~120-460bps gross-margin hit) don't reverse; H2 recovery fails | 35% | -15% | -5.3% |
| R5 | Debt-funded buyback backfires | Levered up to ~1.2x into falling EBITDA; if EBITDA keeps falling, leverage ratio climbs and buyback looks like financial engineering | 25% | -15% | -3.8% |
| R6 | Private-label / competitive entry | RTD protein category growing >10% draws new entrants; shelf is contestable | 40% | -8% | -3.2% |
| R7 | Capital-allocation error repeats | Tanner team did the OWYN deal; another aggressive M&A swing could destroy capital | 20% | -12% | -2.4% |
Sum of expected drag: ~-38.6%. These are not fully independent (R1, R2, R4 correlate — a GLP-1-driven category contraction would simultaneously hit Atkins volume and pricing power). The tail scenario is a structural category decline where branded nutrition becomes a commodity and the $1.85B of acquired intangibles keep getting written down toward a much lower tangible reality.
Crucial mitigant — the downside floor. This is what makes the name interesting rather than a falling knife:
- Asset-light + high FCF. ~$150M FCF on minimal capex means the business self-funds even in decline; it can de-lever fast.
- Conservative balance sheet. Net debt ~1.2x EBITDA, cash $107M, no near-term maturity wall, interest covered ~10x by EBIT. The impairment was 100% non-cash — cash interest was only $9.8M for the half.
- Optionality is nearly free. At $11.94 ~ the bear-case DCF (~$11.91), you pay almost nothing for Quest's growth or any Atkins stabilization.
4. Phase 2 — Financial analysis
4.1 Multi-year record ($000s, AlphaVantage / 10-K)
| FY (Aug) | Revenue | Gross profit | Op income | Op margin | Net income | OCF | Capex | FCF |
|---|---|---|---|---|---|---|---|---|
| 2020 | 816,641 | 309,069 | 113,849 | 13.9% | 65,638 | 58,921 | 1,736 | 57,185 |
| 2021 | 1,005,613 | 392,784 | 180,927 | 18.0% | 40,880 | 132,089 | 6,706 | 125,383 |
| 2022 | 1,168,678 | 428,276 | 203,325 | 17.4% | 108,574 | 110,095 | 5,756 | 104,339 |
| 2023 | 1,242,672 | 436,004 | 204,949 | 16.5% | 133,575 | 168,423 | 12,188 | 156,235 |
| 2024 | 1,331,321 | 494,649 | 221,021 | 16.6% | 139,309 | 214,505 | 6,473 | 208,032 |
| 2025 | 1,450,920 | 508,847 | 218,635 | 15.1% | 103,614 | 178,457 | 20,542 | 157,915 |
Revenue compounded ~12%/yr (FY20-25) — organic plus the OWYN bolt-on. Operating income was remarkably stable at ~$200-221M until FY25's margin dip (integration costs + commodity/tariff pressure). FCF averaged ~$140-160M with trivial capex. This is a high-quality operating engine.
4.2 ROE / ROIC — read carefully (the accounting trap)
Reported ROE looks mediocre (~5.7% FY25, ~6-7% average) and ROE went negative TTM (-6.4%) because of the impairment. But this is an artifact of a balance sheet dominated by $1.85B of goodwill + intangibles from three acquisitions (Atkins via the 2017 SPAC, Quest 2019 ~$1B, OWYN 2024 ~$280M). The denominators are inflated by purchase accounting.
The economically meaningful return is on tangible operating capital: a brand-marketing business with $1.45B sales, ~$160M FCF, and almost no fixed assets earns very high returns on the capital actually employed in operations. DuPont on reported equity is misleading here; the right frame is cash return on invested capital including the acquisition price. On ~$1.5B of cumulative invested capital (debt + equity net of cash), pre-impairment NOPAT of ~$160M is roughly a **10-11% ROIC** — only modestly above an ~8-9% WACC. So as a capital-allocation story (what they paid for the brands) the spread is thin; as an operating story (the brands' own economics) it is excellent. The gap between those two is the entire investment question.
4.3 Owner earnings / FCF
Normalized owner earnings ~ OCF $178M - maintenance capex $15-20M ~ **$155-160M**. At a $1.08B market cap that is a ~14% FCF yield, or $1.66/share of FCF -> a forward P/FCF of ~7.2x. Even haircutting for the FY26 EBITDA decline (-4% to +1% guided), a mid-cycle FCF of ~$140-150M still yields ~13%.
4.4 My own valuation (DCF, explicit assumptions)
Discount rate 9-10% (small/mid-cap, single-category, some cyclicality but low beta 0.16 and recurring consumption). Net debt $289M, 90.5M shares.
| Scenario | Assumptions | Implied EV | Equity value | Per share |
|---|---|---|---|---|
| Bear | FCF starts $140M, -2%/yr for 3yr, +1% thereafter, 0% terminal, 10% disc | ~$1.37B | ~$1.08B | ~$11.9 |
| Base | FCF $155M, +2% for 3yr, +4% mid, 2% terminal, 10% disc | ~$2.11B | ~$1.83B | ~$20.2 |
| Bull | FCF $165M, +5% for 3yr, +6% mid, 2.5% terminal, 9% disc | ~$3.16B | ~$2.87B | ~$31.7 |
The current price is the bear case. Base case is ~70% upside; bull (Quest keeps compounding, OWYN recovers, Atkins stabilizes, margins return to ~36%+) roughly triples.
4.5 Relative valuation (own work, no analyst inputs)
Branded packaged-food/snacking peers typically trade 10-14x EV/EBITDA and ~18-25x earnings in normal times. SMPL at **6x EV/EBITDA** and ~7x forward FCF is priced like a secularly declining business, not a brand with a double-digit-growth flagship. The discount is the opportunity and the warning: the market is rarely this cheap on a CPG name without a reason, and here the reason (Atkins runoff + GLP-1 + OWYN error) is legitimate.
5. Phase 3 — Moat analysis
Moat type: brand + shelf/distribution, narrow and bifurcating.
- Quest: a genuine narrow moat — leading position in high-protein snacking, salty-snack innovation, retailer pull, repeat purchase. Brand + velocity + shelf real estate are self-reinforcing. This is the durable asset.
- Atkins: an eroding moat. The brand still has 75% of sales in top-half-velocity SKUs, but it is tied to a weight-loss paradigm (low-carb) that GLP-1 pharmacology can substitute. Losing distribution is the visible symptom of a weakening franchise.
- OWYN: a nascent, unproven position in clean/plant-based RTD — "leading clean option," but the impairment says the market it was bought into is smaller/slower than underwritten.
Durability test. Quest's moat could last 10-15+ years if it keeps winning innovation and shelf. Atkins's moat is on a 3-7-year fuse depending on GLP-1 adoption and retailer patience. Pricing power exists in Quest, is weak in Atkins (commodity + tariff costs are eating margin and can't be fully passed). Net: a narrow, partly melting moat — not the wide, stable moat Buffett prefers, but not nothing.
6. Phase 4 — Synthesis
6.1 The superinvestor signal, honestly weighed
Howard Marks / Oaktree opened a new but tiny 0.38% position in Q1 2026. Oaktree's DNA is distressed and deep value — buying good-enough assets at prices that discount a bad outcome. A 0.38% weight is a toe in the water, not a high-conviction bet; it says "the asymmetry is interesting at this price," not "this is a franchise compounder." That is exactly the right read here: the value is in the price and the FCF floor, not in certainty about the brands. I treat it as confirmation of the asymmetry, not as a reason to override my own risk register.
6.2 Expected-return tree (3-year)
| Outcome | Prob. | Per-share value | Weighted |
|---|---|---|---|
| Bull (Quest compounds, OWYN recovers, margins ~36%+) | 25% | $31.7 | $7.9 |
| Base (low-single-digit growth, margins normalize) | 40% | $20.2 | $8.1 |
| Bear (Atkins runoff, flat-to-down FCF) | 25% | $11.9 | $3.0 |
| Tail (GLP-1 structural decline, further impairments) | 10% | $6.5 | $0.7 |
| Expected value | ~$19.6 |
Probability-weighted value $19.6 vs $11.94 price -> **+64% expected upside**, with a ~10% tail to ~$6.5 (-46%). Reward/risk is favorable, if you size for the tail.
6.3 Position sizing
Quality B-, narrow/melting moat, real tail risk -> small position only. Target 1.0-2.0% of a diversified portfolio, scaled in. This is a "cheap optionality with a cash floor" position, not a core compounder. Match Oaktree's humility on weight.
6.4 Entry discipline
- **Strong Buy < $9.50** — prices in a worse-than-guided Atkins and still leaves >15% FCF yield and a margin of safety to the bear DCF.
- Accumulate < $11.00 — a ~7-8% pullback from here; pay below the bear-case DCF.
- Current $11.94 = WAIT — fairly priced for the bear case; I want either a lower entry or H2 FY2026 confirmation. No urgency given the tail.
6.5 Monitoring triggers (pre-committed)
| Watch | Bullish confirm | Bearish exit/avoid |
|---|---|---|
| Quest consumption | Stays double-digit | Decelerates < 5% |
| Atkins decline | Stabilizes toward -10% or better by H2 FY26 | Worsens beyond -20%, no flowback |
| Gross margin | Recovers to mid-36% by Q4 FY26 (as guided) | Stuck below 34% into FY27 |
| OWYN | Velocity recovers, no further write-down | Second impairment / continued quality issues |
| Leverage | Holds ~1x, buyback continues | Net debt/EBITDA climbs > 2x on falling EBITDA |
| GLP-1 | Atkins "companion" study converts to distribution wins | Category consumption rolls over |
| Capital allocation | Buybacks at <$12, no large M&A | Another debt-funded acquisition |
7. Bull vs bear (steelman both)
Bull. You're buying a 14%-FCF-yield, asset-light brand business at ~6x EBITDA and 0.7x book, with a double-digit-growth flagship (Quest), management retiring ~11% of the share count at depressed prices, a non-cash impairment that creates accounting fear but no cash impact, and a free option on Atkins stabilizing and OWYN recovering. The market is extrapolating one bad year into permanent decline.
Bear. You're buying a company whose largest legacy brand is in a -20% distribution death spiral, whose only recent acquisition was just written down 65%+ (management overpaid and admitted it), whose entire category sits under the GLP-1 cloud, whose margins are being squeezed by cocoa/whey/tariffs, and whose management is levering up to buy back stock into falling EBITDA — a classic way to look smart until the EBITDA keeps falling. "Cheap" can stay cheap if the cash flows quietly shrink.
Both are coherent. That is precisely why this is a WAIT at $11.94 and a buy several dollars lower — the price needs to compensate for genuine, not imaginary, deterioration.
8. Conclusion
Simply Good Foods is a legitimately cheap, cash-rich, asset-light branded-nutrition business priced for its bear case, with a real growth engine in Quest and a real value-trap risk in Atkins/GLP-1. Howard Marks's small new position correctly frames it as asymmetric optionality, not a sure thing. I reach the same conclusion independently: attractive risk/reward, but only with a margin of safety below today's price and/or H2 FY2026 confirmation. WAIT now; accumulate < $11; back up the truck (small) < $9.50.
Primary-source citations
- SEC 10-Q Q2 FY2026 (period ended 2026-02-28), Note 4 Goodwill & Intangibles and MD&A: "$187.0 million for OWYN and $62.0 million for Atkins"; total "Loss on impairment 249,000"; "net sales decreased 9.4% to $326.0 million"; balance sheet — Total stockholders' equity $1,489,825K, Long-term debt $396,866K, Cash $107,444K, Goodwill $589,974K, Total assets $2,125,704K.
- SEC 10-K FY2025 (period ended 2025-08-30): business description, brand portfolio, fiscal-year convention.
- Q1 FY2026 earnings call transcript (period ended 2025-11-29): "Quest net sales grew nearly 10%... Atkins and OWYN declined 17% and 3%"; "Consumption in Q1 grew 2%, led by double-digit growth from Quest and OWYN, which combined to generate 71% of our net sales"; "we borrowed an incremental $150 million... repurchased over 7% of our common stock... Board authorized a $200 million increase"; FY26 guidance "net sales growth... negative 2% to positive 2%"; GLP-1 pilot study commentary.
- AlphaVantage INCOME_STATEMENT / BALANCE_SHEET / CASH_FLOW / COMPANY_OVERVIEW (SMPL): multi-year financials; TTM revenue $1.416B, EPS TTM -$1.13, EV/EBITDA 9.06 (overview), book value $18.25, shares 90.489M, insiders 8.84%.
- AlphaVantage TIME_SERIES_DAILY_ADJUSTED (SMPL): price $11.94 (2026-06-05), 52-wk high $34.12 / low $10.44, 1-yr return -64%.